Member Info for Merchantbanker

Now valued £7m less than the proposed Abingdon IPO. With a core business that should support most of this value, and an Antigen test to be self branded, ODX are a much better proposition.

Remember the last presentation......... Colin King said that scale up was in relation to Moonshot. ODX are preparing to support mass testing

Okehurst even with the most optimistic view of their RNS, for which i will save the debate away from here, Omega are expecting imminent transfer of Mologic test. Mologic we know we're already working on both saliva and swab, so it will be interesting what comes to market. But you are right there is a huge step from lab to market, and so far Affimers have never been proved outside of the lab. Mologic on the other hand are industry experts with a proven track record. Omega do not need any other test no matter who wants their capacity.

The Mologic test i am confident will be announced as CE marked very soon.

Come off it Okehurst, after today's RNS on AVCT you think ODX opportunity still lies in Avacta's test?

BBI are not in the same league as Mologic in terms of their ability to develop a test.

Do not focus on IP.... all you need to focus on is how much it can be made for and how much is received for selling, and volume.

ABC-19 test we have a profit share for non gov sales.
Mologic we are legal manufacturer.

Ownership of IP will not change this equation.

JDT - Sorry but it's not a gloat. Just do yourselves a favour and go back and reconsider the earlier news flow after reading today's RNS.

I spent a whole day over the weekend going back over Avacta, I wanted to make sure what i thought about the company was fair. I've read every RNS, watched every interview and everything there is to read from the start of the year. At no point has AS communicated the risk level here. Everything has been spoken about as if a perfect storm of achieving milestones that quite frankly are far from guaranteed. The chance of success has been communicated as if 100%, when in reality it was always probably no more than 25%. That's the problem i have, you have to allow the market to price it at a fair risk reward level.

I don't write Avacta off as a company by any means, but for a small company like that to sell such big dreams is wrong. You have to deliver and prove up your capabilities first. I read a quote where AS claimed to be as big as Roche, Thermo Fisher etc in the future. I mean fair play for having some ambition, but a public listed company has to prove themselves before making such claims. You have to enhance your profile as you grow and deliver.

Sorry all not what you wanted to hear. Alarm bells have been ringing, perhaps time to give them some proper thought.

It's been clear saliva was a problem since Jon Bell's interview.

This test was sold as a high performing test which was much quicker and more effective than any alternative. It's clear they are struggling with performance, and there is no USP here. The manufacturing capacity they have secured is much lower than what has been suggested. If they do ever get a test ready, manufacturing capacity will already be eaten up. If Affimers have no performance advantage over other reagents, the industry will likely stick with what has been tried and tested.

Fair play to Avacta for giving it a go, but they should have been more honest and transparent enabling the market to price at a fair risk reward level. T%hey clearly haven't given up but i suspect other products are going to start hitting the market very soon.

Perhaps read the thread.... it was already being discussed.

I absolutely think their has to be consolidation in the industry. It is too fragmented to be efficient. The cream will rise to the top. Even some of the large pharma that don't have a diagnostics arm will lose significant ground to those that do. It is a licence to print money. But it also shows what can be done and will drive the science to look at other areas cheap POC tests can be used.

Personally i think one of the problems with rolling out mass testing is the political aspect. Enabling tests from either anitbody immunity or short term negative antigen test passports creates a problem in society with privileges. I strongly believe this is the hold up with MHRAS approval and the ready availability of tests to the end user. The vaccine roll out takes away that political aspect because the vaccine starts to do the same, allow privileges, but with a vaccine it is a necessary step and vastly increases the scope of privileges. So that is another reason i believe a vaccine opens up the lateral flow market.

End game depends of there is a buyout. With no buyout there is no endgame as this pandemic is transforming a new diagnostics business in the UK. Diagnostics will grow far beyond covid.

Fredluck - Abingdon state they have 3 antigen tests under contract manufacturing. So they clearly have zero reliance on any 1 test. Personally i wouldn't see it as much of a vote of confidence by not reserving capacity for 1 specific test. The rationale for their listing and fundraising is largely based on ABC-19 test opportunity. Also their capacity appears smaller than people may have thought. Circa 1m by YE going up to 3m. So 3m capacity for 4 tests, one of which is much more profitable. We know BBI are smaller than Abingdon. Didn't AS promise 10m capacity from the 2 companies? They don't even have 10m and they already have other commitments.
ODX never signed up because they have an agreement with Mologic who have proven credentials in diagnostics where ODX are legal manufacturer and have 3 tests, all of which are either or been used in live trials and we have seen physical evidence of the existence of those tests. There is still zero evidence that this test is going to work and make it to market.

Could delaying it 2 weeks increase the value of a large government contract and MHRA approval lands?

Looks like IPO pushed back a couple of weeks. It appears they have 3 customers for Antigen tests.

"The Company is also working with three customers to transfer their Covid-19 antigen tests to manufacture"

https://www.sharesmagazine.co.uk/news/market/LSE20201119080002_3785030/Schedule-One-Abingdon-Health-PLC

It says they are working with 3 customers to transfer Antigen tests tech. Mologic ?!

https://www.sharesmagazine.co.uk/news/market/LSE20201119080002_3785030/Schedule-One-Abingdon-Health-PLC

Poundcake - I didn't post that.

It's a sad example of AIM investors throwing money at whichever stocks make the most noise and promises rather than those that are fundamentally executing a profitable business plan.
ODX do not need to shout from the rafters to sell covid tests, food tests or CD4 tests. They have proven distributions channels and direct links to key buyers.
Omega have mapped out their plan with capacity increase and product milestones. Everything is going we, the Lateral Flow market is just about opening up now.
Omega have the luxury of the two most sought after lateral flow tests in the world. The strategy, capacity, products, market and profitability is all out there. It is really not difficult to understand, to calculate the profitability and therefore future value and the high chances of success.

Solid morning here. Enjoy the rise.

There is nothing more they can say other than they are building capacity up to 2-2.5m by April based on expected demand after conversations with stakeholders. They are currently selling everything they are making, with Nov capacity already consumed. The 2 main products also still have major milestones to achieve to enable sales.